Showing results (11-20 of 157) with videos related to
Sort By:
Pageof 16
Current Oncology Reports|March 22, 2012
Management of hepatocellular carcinoma: beyond sorafenibStephen L Chan, Tony Mok, Brigette B Y MaLung Cancer (Amsterdam, Netherlands)|June 17, 2022
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapiesMelissa Johnson, Marina Chiara Garassino, Tony Mok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel StrategiesAntonio Passaro, Julie Brahmer, Scott Antonia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 TrialChee Khoon Lee, Silvia Novello, Anna Rydén, et al.Translational Lung Cancer Research|December 9, 2017
Blood-based tumor biomarkers in lung cancer for detection and treatmentHirva Mamdani, Shahid Ahmed, Samantha Armstrong, et al.Expert Opinion on Drug Safety|December 9, 2010
Reviewing the safety of erlotinib in non-small cell lung cancerMartin Reck, Tony Mok, Jürgen Wolf, et al.Clinical Lung Cancer|December 14, 2011
Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic reviewPaul Mitchell, Tony Mok, Helen Barraclough, et al.Journal of Cellular and Molecular Medicine|August 8, 2014
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCLuis Paz-Ares, Denis Soulières, Joachim Moecks, et al.Lancet (London, England)|August 27, 2013
Management of non-small-cell lung cancer: recent developmentsMartin Reck, David F Heigener, Tony Mok, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2020
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR MutationsAntonio Passaro, Tony Mok, Solange Peters, et al.Pageof 16